BioNTech tests new cancer drug targeting specific protein in advanced tumors
NCT ID NCT05262530
Summary
This early-stage trial tested a new drug called BNT142 in people with advanced solid tumors that have a specific marker called CLDN6. The study aimed to find a safe dose and see if the drug could shrink tumors in patients with cancers like ovarian, lung, and testicular cancer who had run out of standard treatment options. The trial was terminated early, and its main goals were to check for side effects and gather initial signs of whether the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Churchill Hospital - Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 7LE, United Kingdom
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
-
HM Nou Delfos General Hospital
Barcelona, 08023, Spain
-
Hammersmith Hospital, Imperial College School Of Medicine - Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Hospital Universitario 12 de Octubre - Centro de Actividades Ambulatorias
Madrid, 28041, Spain
-
Hospital Universitario Vall D'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen de la Victoria Campus Universitario de Teatinos
Málaga, 29010, Spain
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National University Cancer Institute - National University Hospital
Singapore, 119074, Singapore
-
START Madrid CIOCC Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
South Texas Accelerated Research Therapeutics (START) - San Antonio
San Antonio, Texas, 78229, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, L7 8YA, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.